NCT03032107View on ClinicalTrials.gov

A Study Of Pembrolizumab In Combination With Trastuzumab-DM1

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

February 17, 2017

Primary Completion Date

October 29, 2020

Study Completion Date

December 5, 2024

Conditions
Breast Cancer
Interventions
DRUG

T-DM1

-T-DM1 will be administered intravenousely in clinic on day 1 of each 3-week cycle

DRUG

Pembrolizumab

-Pembrolizumab will be administered intravenousely in clinic on day 1 of each 3-week cycle

Trial Locations (2)

02215

Beth Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER

NCT03032107 - A Study Of Pembrolizumab In Combination With Trastuzumab-DM1 | Biotech Hunter | Biotech Hunter